Market Newsdesk

FARGO, N.D. and BOSTON, Aug. 10, 2021 /PRNewswire/ — Aldevron, a leading research to GMP biomanufacturer of plasmid DNA, mRNA, and proteins, and Ginkgo Bioworks, Inc. (“Ginkgo”) today announced a manufacturing breakthrough driven by their strategic partnership. Aldevron has a successful history of manufacturing high-quality components that enable breakthroughs in the emerging field of genetic medicine. Aldevron is currently experiencing a period of rapid growth, including expanding its manufacturing facilities and adding new products to its growing catalog. Ginkgo, which recently announced a business combination with Soaring Eagle Acquisition Corp. (Nasdaq: SRNG), is building the leading platform for cell programming, enabling customers across industries to improve products and manufacturing processes for greater efficiency and sustainability. 

Ginkgo and Aldevron have been working together in a partnership formed earlier this year to optimize production of mRNA vaccine components. The partnership has already resulted in significant breakthrough improvements in manufacturing yield of the vaccinia capping enzyme (VCE), a component that is often required to produce mRNA therapies and vaccines. Aldevron has the exclusive rights to the protocol conditions of the newly developed manufacturing process, which is over 10-times more efficient than the previous process.

“Aldevron’s industry-leading products and services are the foundation for some of the most exciting advances in biological science today,” said Jason Kelly, CEO of Ginkgo Bioworks. “This partnership represents a momentous growth opportunity for Aldevron as it continues to bolster its already expansive portfolio of products, and an exciting milestone for Ginkgo as we continue to expand our capabilities into the pharmaceutical ecosystem. Aldevron has been a great partner with us on improving VCE, which we see as a key ingredient to scaling mRNA production globally.”

“I’m very excited about combining the additive strengths of Ginkgo Bioworks’ development expertise and Aldevron’s manufacturing horsepower to yield an optimized manufacturing method for vaccinia capping enzyme,” said Tom Foti, President of Aldevron’s Protein Business Unit. “Historically this enzyme has been difficult to produce, and we believe this yield breakthrough will accelerate mRNA therapeutic and vaccine development for manufacturing teams around the world.”

About Aldevron
Aldevron is a premier manufacturing partner in the global genetic medicine field. Founded in 1998 by Michael Chambers and John Ballantyne, the company provides critical nucleic acids and proteins used to make gene and cell therapies, DNA and RNA vaccines, and gene editing technologies. Aldevron’s 700+ employees support thousands of scientists who are developing revolutionary treatments for millions of people.

Media Contact for Aldevron:

Ellen Shafer

Senior Director of Marketing and Communications
[email protected] 
701.297.9256

About Ginkgo Bioworks
Ginkgo is building a platform to enable customers to program cells as easily as we can program computers. The company’s platform is enabling biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. Ginkgo is also actively supporting a number of COVID-19 response efforts, including K-12 pooled testing, vaccine manufacturing optimization and therapeutics discovery. In May 2021, Ginkgo announced a business combination with Soaring Eagle Acquisition Corp. (Nasdaq: SRNG), which, if completed, will result in Ginkgo, through a parent entity, Ginkgo Bioworks Holdings, Inc., becoming a public company. The transaction is expected to close in the third quarter of 2021, subject to regulatory and shareholder approvals, and other customary closing conditions. For more information, visit www.ginkgobioworks.com.

MEDIA CONTACT:

[email protected]

INVESTOR CONTACT:

[email protected]

ADDITIONAL LEGAL INFORMATION

Forward-Looking Statements Legend

This document contains certain forward-looking statements within the meaning of the federal securities laws with respect to the proposed transaction between Ginkgo and Soaring Eagle Acquisition Corp. (“SRNG”), including statements regarding the benefits of the transaction, the anticipated timing of the transaction, the services offered by Ginkgo and the markets in which it operates, and Ginkgo’s projected future results. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this document, including but not limited to: (i) the risk that the transaction may not be completed in a timely manner or at all, which may adversely affect the price of SRNG’s securities, (ii) the risk that the transaction may not be completed by SRNG’s business combination deadline and the potential failure to obtain an extension of the business combination deadline if sought by SRNG, (iii) the failure to satisfy the conditions to the consummation of the transaction, including the adoption of the agreement and plan of merger by the shareholders of SRNG and Ginkgo, the satisfaction of the minimum trust account amount following redemptions by SRNG’s public shareholders and the receipt of certain governmental and regulatory approvals, (iv) the lack of a third party valuation in determining whether or not to pursue the proposed transaction, (v) the occurrence of any event, change or other circumstance that could give rise to the termination of the agreement and plan of merger, (vi) the effect of the announcement or pendency of the transaction on Ginkgo business relationships, performance, and business generally, (vii) risks that the proposed transaction disrupts current plans of Ginkgo and potential difficulties in Ginkgo employee retention as a result of the proposed transaction, (viii) the outcome of any legal proceedings that may be instituted against Ginkgo or against SRNG related to the agreement and plan of merger or the proposed transaction, (ix) the ability to maintain the listing of SRNG’s securities on Nasdaq, (x) volatility in the price of SRNG’s securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo plans to operate, variations in performance across competitors, changes in laws and regulations affecting Ginkgo’s business and changes in the combined capital structure, (xi) the ability to implement business plans, forecasts, and other expectations after the completion of the proposed transaction, and identify and realize additional opportunities, and (xii) the risk of downturns in demand for products using synthetic biology. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of SRNG’s proxy statement/prospectus relating to the transaction, and in SRNG’s other filings with the Securities and Exchange Commission (the “SEC”). SRNG and Ginkgo caution that the foregoing list of factors is not exclusive. SRNG and Ginkgo caution readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Neither SRNG nor Ginkgo undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.

Additional Information and Where to Find It

This document relates to a proposed transaction between Ginkgo and SRNG. This document does not constitute an offer to sell or exchange, or the solicitation of an offer to buy or exchange, any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, sale or exchange would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. In connection with the proposed transaction, SRNG filed a registration statement on Form S-4/A with the SEC on August 3, 2021, which included a proxy statement of SRNG and a prospectus of SRNG. The definitive proxy statement/prospectus will be sent to all SRNG shareholders as of the record date to be established for voting on the proposed business combination and Ginkgo stockholders. SRNG also will file other documents regarding the proposed transaction with the SEC. Before making any voting decision, investors and security holders of SRNG and Ginkgo are urged to read the registration statement, the proxy statement/prospectus and all other relevant documents filed or that will be filed with the SEC in connection with the proposed transaction as they become available because they will contain important information about the proposed transaction.

Investors and security holders may obtain free copies of the proxy statement/prospectus and all other relevant documents filed or that will be filed with the SEC by SRNG through the website maintained by the SEC at www.sec.gov. In addition, the documents filed by SRNG may be obtained free of charge by written request to SRNG at 955 Fifth Avenue, New York, NY, 10075, Attention: Eli Baker, Chief Financial Officer, (310) 209-7280.

Participants in Solicitation

SRNG’s and Ginkgo and their respective directors and officers may be deemed to be participants in the solicitation of proxies from SRNG’s stockholders in connection with the proposed transaction. Information about SRNG’s directors and executive officers and their ownership of SRNG’s securities is set forth in SRNG’s filings with the SEC. To the extent that holdings of SRNG’s securities have changed since the amounts printed in SRNG’s proxy statement, such changes have been or will be reflected on Statements of Change in Ownership on Form 4 filed with the SEC. Additional information regarding the interests of those persons and other persons who may be deemed participants in the proposed transaction may be obtained by reading the proxy statement/prospectus regarding the proposed transaction when it becomes available. You may obtain free copies of these documents as described in the preceding paragraph.

View original content to download multimedia:https://www.prnewswire.com/news-releases/aldevrons-collaboration-with-ginkgo-bioworks-yields-manufacturing-breakthrough-for-vaccinia-capping-enzyme-used-for-manufacturing-of-mrna-vaccines-301351786.html

SOURCE Ginkgo Bioworks

LEXINGTON, Mass., Aug. 10, 2021 /PRNewswire/ — iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online marketplace for human biospecimens, today reported its financial results for the three-month period ended June 30, 2021.

“During the second quarter of 2021, iSpecimen successfully completed its initial public offering and began trading on the Nasdaq Capital Market. This is both a significant milestone and the starting point of a new and exciting chapter for the Company,” said Christopher Ianelli, MD, PhD, CEO and President of iSpecimen. “During the quarter, we continued to deliver exceptional financial and operating performance, posted revenue growth of 93% on a year-over-year basis and increased the number of registered research users on the iSpecimen Marketplace™ by 40% year-over-year to more than 3,800 users. With our enhanced capital position, iSpecimen is well-positioned to expand and scale its operations, with the goal of becoming the preeminent, online marketplace for human biospecimens.”

“We continue to broaden our supply network and data assets while improving our technology platform, which should accelerate our sales and revenue momentum as more suppliers and customers embrace the iSpecimen Marketplace. Through our continued expansion, iSpecimen is disrupting the biospecimen procurement process, providing instant access to a vast repository of biospecimens and patient data from a global network of healthcare organizations, thereby empowering researchers to advance scientific discovery,” concluded Dr. Ianelli. 

Q2 2021 Financial & Operational Updates

• Revenue increased 93% to $2.9 million for the second quarter of 2021, compared to $1.5 million for the same period in 2020.
• Cash and cash equivalents were $13.2 million as of June 30, 2021.
• Unique supplier organizations under agreement were 190 as of June 30, 2021, an increase of 33 organizations year-over-year.
• Unique customer organizations with purchases totaled 378 as of June 30, 2021, an increase of 74 new customer organizations year-over-year.
• iSpecimen Marketplace had surpassed 3,800 registered research users as of June 30, 2021, up 40% year-over-year.
• As of June 30, 2021, iSpecimen’s received $8.8 million in purchase orders in 2021, up 31% year-over-year.

Recent Corporate Updates

• Closed its initial public offering (“IPO”) of 2,250,000 shares of common stock at a public offering price of $8.00 per share on June 21, 2021, for aggregate proceeds of $18 million. On July 1, 2021, the Company sold an additional 337,500 shares of its common stock, pursuant to the underwriters’ full exercise of the overallotment option, at a public offering price of $8.00 per share, for aggregate gross proceeds of $2.7 million. In total, the Company received approximately $18.2 million in net proceeds, after deducting for all underwriting discounts of approximately $1.9 million and other offering costs of approximately $0.6 million. In conjunction with its IPO, the Company began trading on the Nasdaq Capital Market under the ticker symbol “ISPC” on June 17, 2021.
• In connection with the IPO, the Company eliminated approximately $29.0 million of liabilities and mezzanine classifications from the balance sheet, resulting in $3.0 million of bridge debt remaining outstanding.
• Enhanced the Board of Directors with the appointments of John Brooks and Margaret Lawrence.
• Mr. John Brooks currently serves as Managing Director of Healthcare Capital LLC, an investment company that advises early-stage life sciences companies.
• Ms. Margaret Lawrence currently serves as a General Manager of Wayfair Professional, one of the world’s largest online destinations for home goods.

Financial Results for the Second Quarter of 2021

Revenue for the second quarter of 2021 increased 93% to approximately $2.9 million, compared to approximately $1.5 million for the same period in 2020. The 93% year-over-year increase was primarily due to the success of iSpecimen’s maturing sales team, continued demand for specimens from patients with known COVID-19 test results, and an increasing demand for specimens in non-COVID-19 research areas.

Cost of revenue was approximately $1.5 million for the second quarter of 2021, compared to approximately $0.5 million for the second quarter of 2020. This increase was attributable to an 8% increase in the number of specimens accessioned as well as a 191% increase in the average cost per specimen due to the specimen mix during the second quarter of 2021, compared to the prior year period. In addition to the increase in the average cost per specimen in 2021 being related to specimen mix, a significant project in 2020, which yielded a sizably lower than average cost per specimen, significantly impacted the magnitude of the year over year difference in the average cost per specimen.

General and administrative expenses were approximately $1.5 million for the second quarter of 2021, compared to approximately $0.3 million for the second quarter 2020. The increase was primarily attributable to an increase in costs related to becoming a public company including an increase in legal and accounting expenses, an increase of other general and administrative expenses across the board related to amortization of internally developed software, associated software licenses, human resource related expenses, insurance costs and facility expenses, an increase in director and officer insurance, and an increase in payroll related costs for the chief financial officer. Additionally, the remaining increase is related to costs not expected to recur in the future, such as payroll expenses of approximately $0.5 million for a special IPO bonus provided to all employees and increased legal, accounting and consulting expenses of approximately $0.3 million that did not qualify as offering costs.

Net loss was approximately $1.4 million for the second quarter of 2021, compared to approximately $0.2 million for the same period in 2020. This was primarily due to higher operating expenses partially offset by an increase in revenue, all associated with the factors mentioned above.

Cash was approximately $13.2 million as of June 30, 2021.

Conference Call and Webcast Information

The Company will host a conference call and audio webcast today, Tuesday, August 10^th at 8:30 a.m. Eastern Time featuring remarks by Christopher Ianelli, MD, PhD, CEO and President, Tracy Curley, CFO and Treasurer, and Jill Mullan, COO and Secretary.

For interested individuals unable to join the conference call, a replay will be available through August 24, 2021, at +1-844-512-2921 (U.S. Toll Free) or +1-412-317-6671 (International). Participants must use the following code to access the replay of the call: 13721607. An archived version of the webcast will also be available on iSpecimen’s Investor Relations site: https://ispecimen.irpass.com/.

About iSpecimen
iSpecimen offers an online marketplace for human biospecimens, connecting life scientists in commercial and non-profit organizations with healthcare providers that have access to patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers, and other healthcare organizations. For more information about iSpecimen, please visit www.ispecimen.com.

Forward Looking Statements
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are characterized by future or conditional verbs such as “may,” “will,” “expect,” “intend,” “anticipate,” believe,” “estimate” and “continue” or similar words. You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forward-looking information.

Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to the risks factors contained in the Company’s filings with the Securities and Exchange Commission, which are available for review at www.sec.gov. Forward-looking statements speak only as of the date they are made. New risks and uncertainties arise over time, and it is not possible for the Company to predict those events or how they may affect the Company. If a change to the events and circumstances reflected in the Company’s forward-looking statements occurs, the Company’s business, financial condition and operating results may vary materially from those expressed in the Company’s forward-looking statements.

Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

For further information, please contact:

Investor Contact
KCSA Strategic Communications
Allison Soss / Scott Eckstein
[email protected]

Media Contact

Kaitlynn Cooney

For iSpecimen
[email protected]
617.587.2811

View original content to download multimedia:https://www.prnewswire.com/news-releases/ispecimen-reports-second-quarter-2021-financial-results-301351561.html

SOURCE iSpecimen Inc.

NEW YORK, Aug. 10, 2021 /PRNewswire/ — As the debate around mask policies for children heading back to school continues to heat up, and a strong desire from many parents to get kids back to in-person learning full time, the question of whether children should wear masks at school is becoming more complicated than ever.

ValuePenguin surveyed more than 1,000 parents with children under 18 to learn more about where parents stood on masks and vaccinations when it comes to heading back to school. 

Key findings:

• 74% of parents with kids younger than 18 support masks for students who haven’t gotten the COVID-19 vaccination. Parents in the Northeast are most supportive (85%), while those in the South are least supportive (67%).
• 44% of parents whose children will attend school in person at least part of the time plan to require their unvaccinated kids to wear masks, and a further 31% will ask their vaccinated kids to mask up. However, 25% won’t require their children to wear masks at school regardless of their vaccination status.
• As the delta variant surges, 44% of parents say their kids won’t go to in-person school full time this fall. That percentage breaks down to 27% opting for a hybrid schedule and 11% for full-time virtual school, as well as 6% who aren’t sure what to do yet.
• On the other hand, 12% of parents changed their child’s school during the pandemic so they could learn in person. Additionally, 32% of parents whose children will attend school in person this fall say their child’s learning suffered at home.
• Though COVID-19 vaccines have been approved for children 12 and older, 31% of parents aren’t comfortable allowing their age-eligible children to get the vaccine. That percentage jumps to 39% among mothers, compared with 21% among fathers.

View full report: https://www.valuepenguin.com/masks-at-school-survey

About ValuePenguin.com: ValuePenguin.com, part of LendingTree (NASDAQ: TREE), is a personal finance website that conducts in-depth research and provides objective analysis to help guide consumers to the best financial decisions. ValuePenguin focuses on value, assessing whether the return of a particular decision is worth the cost or risk of that option, and how this stacks up with the other possible choices they may have. For more information, please visit www.valuepenguin.com, like our Facebook page, or follow us on Twitter @ValuePenguin.

Media Contact:
Nadia Gonzalez (Mrs.)
[email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/more-than-70-of-parents-say-unvaccinated-kids-should-wear-masks-at-school-according-to-a-valuepenguincom-survey-301351740.html

SOURCE ValuePenguin.com

ROCKVILLE, Md. and BEIJING, Aug. 10, 2021 /PRNewswire/ — CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced the Company will host a conference call reviewing the second quarter highlights at 8:00 a.m. ET on Thursday, August 12^th, 2021.

On the call, CASI’s Chairman & CEO will provide an update on the Company’s business and upcoming milestones. The conference call can be accessed by dialing (833) 420-0382 (U.S.), (800) 870-0181 (China), (400) 682-8629 (China, domestic), 58086567 (Hong Kong) to listen to the live conference call. The conference ID number for the live call is 5639775. Participants dialing in via International Toll-Free Service (ITFS) numbers will be required to provide the following passcode to join the conference call: 8336474459, 6025859887.

This call will be recorded and available for replay by dialing (855) 859-2056 (U.S.) or (404) 537-3406 (international) and enter 5639775 to access the replay.

About CASI Pharmaceuticals

CASI Pharmaceuticals, Inc. is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. The Company intends to execute its plan to become a leader by launching medicines in the greater China market leveraging the Company’s China-based regulatory and commercial competencies and its global drug development expertise. The Company’s operations in China are conducted through its wholly-owned subsidiary, CASI Pharmaceuticals (China) Co., Ltd., which is located in Beijing, China. The Company has built a commercial team of more than 80 hematology and oncology sales and marketing specialists based in China. More information on CASI is available at www.casipharmaceuticals.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/casi-pharmaceuticals-to-report-second-quarter-2021-financial-results-and-host-conference-call-august-12-2021-301351836.html

SOURCE CASI Pharmaceuticals, Inc.

TEL AVIV, Israel and SINGAPORE, Aug. 10, 2021 /PRNewswire/ — Innoviz Technologies (Nasdaq: INVZ), a leading provider of high-performance, solid-state LiDAR sensors and perception software, has formed a partnership with Curium, a leading developer of automated calibration services for Autonomous Systems.

Curium’s automated calibration software ensures that the vehicle’s sensor suite is working as it should, even under dynamically changing conditions. This is a critical problem to solve, as sensors which are out of adjustment can lead to mis-detections and accidents.

Through the partnership agreement, Curium will apply its patented calibration techniques to its advanced driving system using the advanced capabilities of Innoviz’s solid-state LiDAR sensor. Curium’s solution actually simplifies the integration of the InnovizOne Lidar into any vehicle, as well as the installation of the sensor in the production stage.

Curium will also distribute and promote Innoviz’s products throughout Southeast Asia across multiple sectors, including automotive original equipment manufacturers (OEMs), shuttles, robotaxis, and various industrial applications. The partnership between the companies builds on Innoviz’s strong relationships in Asia, including Korea, Japan, and China.

“We are pleased to partner with Innoviz Technologies, a company that has by far the best LiDAR on the market,” said Dr. Ali Hasnain, CEO and founder of Curium. “With Innoviz’s market-leading LiDAR solution and Curium’s ability to perform multi-sensor Continuous Dynamic Calibration™, we will be giving both companies a distinct market advantage when it comes to systems that require the best in LiDAR technology with superior levels of reliability. Innoviz’s strong global presence will enable us to work together in Asia and beyond, giving us confidence in a long and fruitful collaboration.”

About Innoviz Technologies

Innoviz is a leading provider of technology that will put autonomous vehicles on roads. Innoviz’s LiDAR technology can “see” better than a human driver and meets the automotive industry’s strict expectations for performance, safety, and price. Selected by BMW for its fully autonomous car program, Innoviz’s technology will be deployed in BMW’s consumer vehicles. Innoviz is backed by top-tier strategic partners and investors, including SoftBank Ventures Asia, Samsung, Magna International, Aptiv, Magma Venture Partners, and others. For more information, visit www.innoviz.tech.

About Curium

Curium is a market leading innovator in sensor calibration technologies with a patent pending solution for multi-sensor calibration. This approach to calibration ensures that development of autonomous systems such as Autonomous Vehicles can be rapidly escalated to level 4 and 5 of automation. This is done by Curium’s ability to perform Continuous Dynamic Calibration™ (CDC) across multiple sensor types such as LiDAR, Radar and Cameras, ensure complete confidence in the accuracy and reliability of the sensor data and therefore enabling AI modules to make accurate decisions all the time, every time. For more information, visit www.curium.sg.

Join the discussion:
Facebook, LinkedIn, YouTube, Twitter

Photo – https://mma.prnewswire.com/media/1591695/Innoviz_Technologies.jpg
Logo – https://mma.prnewswire.com/media/1496323/Innoviz_Technologies_Logo.jpg

Innoviz Technologies

Contact Information

[email protected]

Investor Contact

Maya Lustig

Innoviz Technologies
+972 54 677 8100
[email protected]

Gateway Investor Relations
Cody Slach or Matt Glover
+1 (949) 574-3860 
[email protected]

Curium

[email protected]

Forward Looking Statements

This announcement contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding the services offered by Innoviz, the anticipated technological capability of Innoviz’s products, the markets in which Innoviz operates and Innoviz’s projected future results. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this announcement, including but not limited to, the ability to implement business plans, forecasts, and other expectations, the ability to identify and realize additional opportunities, and potential changes and developments in the highly competitive LiDAR technology and related industries. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in Innoviz’s annual report on Form 20-F filed with the SEC on April 21, 2021 and other documents filed by Innoviz from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Innoviz assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Innoviz gives no assurance that it will achieve its expectations.

View original content to download multimedia:https://www.prnewswire.com/news-releases/innoviz-technologies-partners-with-leading-autonomous-system-provider-curium-to-enable-a-safe-vehicle-calibration-experience-in-southeast-asia-301351944.html

SOURCE Innoviz Technologies

BEIJING, Aug. 10, 2021 /PRNewswire/ — Phoenix New Media Limited (“Phoenix New Media”, “ifeng” or the “Company”) (NYSE: FENG), a leading new media company in China, today announced that it will report its second quarter 2021 financial results on Monday, August 16, 2021 after the market closes. The earnings release will be available on ifeng’s investor relations website at http://ir.ifeng.com.

Following the earnings release, ifeng’s management team will hold a conference call on Monday, August 16, 2021 at 9:00 p.m. Eastern Time (or Tuesday, August 17, 2021 at 9:00 a.m.Beijing/Hong Kong time) to discuss the financial results and operating performance.

Due to the outbreak of COVID-19, operator assisted conference calls are not available at the moment. All participants must preregister online prior to the call to receive the dial-in numbers. Preregistration may require a few minutes to complete.

Conference Call Preregistration

Participants can register for the conference call by navigating to http://apac.directeventreg.com/registration/event/7091964. Once preregistration has been complete, participants will receive dial-in numbers, Direct Event Passcode, and registrant ID by email.

Please dial in 10 minutes prior to the call, using the participant dial-in numbers, Direct Event Passcode and unique registrant ID which would be provided upon registering. You will be automatically linked to the live call after completion of this process.

A replay of the call will be available through August 25, 2021 by dialing the following numbers:

International:                           +61 2 8199 0299
Mainland China:                      4006322162
Hong Kong:                             +852 30512780
United States:                          +1 646 254 3697
Conference ID:                        7091964

A live and archived webcast of the conference call will also be available on the Company’s investor relations website at http://ir.ifeng.com.

About Phoenix New Media
Limited

Phoenix New Media Limited (NYSE: FENG) is a leading new media company providing premium content on an integrated Internet platform, including PC and mobile, in China. Having originated from a leading global Chinese language TV network based in Hong Kong, Phoenix TV, the Company enables consumers to access professional news and other quality information and share user-generated content on the Internet through their PCs and mobile devices. Phoenix New Media’s platform includes its PC channel, consisting of ifeng.com website, which comprises interest-based verticals and interactive services; its mobile channel, consisting of mobile news applications, mobile video application and mobile Internet website; and its operations with the telecom operators that provides mobile value-added services.

For investor and media inquiries please contact

Phoenix New Media Limited
Qing Liu
Email: [email protected]

ICR, Inc.
Robin Yang
Tel: +1 (646) 405-4883
Email: [email protected]

View original content:https://www.prnewswire.com/news-releases/phoenix-new-media-to-announce-second-quarter-2021-financial-results-on-monday-august-16-2021-301351863.html

SOURCE Phoenix New Media Limited

As an innovator in AEC structural simulation and certification for 40 years, S-FRAME Software is a leading advocate for the use of timber in building design

TROY, Mich., Aug. 10, 2021 /PRNewswire/ — Altair (Nasdaq: ALTR), the global leader converging simulation, HPC, and AI, today announced that it has acquired S-FRAME Software, a structural analysis software platform used by engineers to evaluate a structure’s ability to withstand external loads (like wind, water, and snow) and meet design code requirements around the world.

For more 30 years, high-end architectural clients have utilized Altair’s sophisticated technology – which is also used to design high-tech modern aircraft and automobiles – to develop some of the world’s most innovative and iconic structures. Utilizing S-FRAME Software’s finite element structural analysis and code support with Altair’s high-fidelity structural optimization solutions will allow architects and civil engineers to be more innovative and bring their visions to life while adhering to local code requirements.

According to CIMdata, the leader in product lifecycle (PLM) education and research, “the AEC segment will be one of the fastest-growing segments of the PLM market with a 14.7 percent CAGR to $11 billion in 2025.”

“We are excited to expand our presence in the rapidly growing AEC market to lead the transformation from rule-based design to predictive, high-performance design, fueled by simulation,” said James R. Scapa, founder and chief executive officer, Altair. “By using highly sophisticated performance-based, predictive simulation, architects and designers will be able to be more creative, fueling innovation while increasing safety.”

As an AEC innovator for many years, S-FRAME Software’s integrated solutions make it possible to analyze, design, and detail structures regardless of geometric complexity, loading conditions, nonlinear effects, design code requirements, or material type including steel, concrete, composites, or mass timber, one of the hottest in sustainable building materials. S-FRAME Software has been a leading advocate for the use of timber in building design as the material offers sustainability through greenhouse gas reduction and other environmental benefits like insulation as well as architectural aesthetics. S-FRAME Software also allows users to produce comprehensive and detailed design reports that include clause references and intermediate results for multiple design code support.

“Joining the Altair team is a strategic way to accelerate our growth and become part of a full solutions suite with their advanced structural design offerings,” said Marinos Stylianou, chief executive officer, S-FRAME Software. “We are confident our combined offerings will be able to empower engineers, designers, and builders to reach new heights.”

Founded in 1981, S-FRAME Software is based in British Columbia, Canada and serves a global client base.

S-FRAME Software will be available via Altair Units, Altair’s patented, subscription-based licensing model, which allows organizations to pay only for what their employees need, when they need it.

About Altair (Nasdaq: ALTR)

Altair is a global technology company that provides software and cloud solutions in the areas of simulation, high-performance computing (HPC), and artificial intelligence (AI). Altair enables organizations across broad industry segments to compete more effectively in a connected world while creating a more sustainable future. To learn more, please visit www.altair.com.

Media Contacts

Corporate

Jennifer Ristic

+1.216.849.3109
[email protected]

Altair Europe/The Middle East/Africa

Evelyn Gebhardt

+49 7031 6208 0
[email protected]

Investor Relations

The Blueshirt Group
Monica Gould +1 212.871.3927
[email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/altair-acquires-s-frame-software-powerful-structural-analysis-and-design-software-to-strengthen-and-accelerate-global-footprint-in-architecture-engineering-and-construction-aec-301351474.html

SOURCE Altair